IRVINE, CA--(Marketwire - Oct 1, 2012) - Itonis, Inc. (PINKSHEETS: ITNS) and Charles Hensley, Ph.D., the inventor of the Zicam® Cold Remedy, and founding member of Itonis Pharmaceuticals, are pleased to announce that the organization of the first clinical trial of the recently announced over-the-counter and prescription homeopathic nasal spray for the treatment of nausea has commenced. The company plans to announce over the coming weeks full details of the double blinded, placebo-controlled clinical trial.
Dr. Hensley commented, "I've been working on the formulation for an over-the-counter, systemically active preparation delivered via a nasal spray for the alleviation of mild to moderate nausea. While there is considerable anecdotal indication that this preparation will be both safe and effective, we feel it is time for the rubber to meet the road in an Institutional Review Board controlled clinical study setting. We are actively organizing the study and look forward to announcing full details very soon."
While the size of the market for anti-nausea related drugs and preparations is not exactly known, Itonis estimates it to be well in excess of $1 billion annually. There have been relatively few innovations within this product category over the past few years and the company believes the market is ripe for a new type of anti-nausea preparation to be available over-the-counter.
About Itonis, Inc. and Itonis Pharmaceuticals
Itonis Pharmaceuticals, a division of Itonis, Inc., is headed by Charles Hensley, Ph.D. This division's mission is to create and market over-the-counter and prescription homeopathic products that better people's lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of Geltech, LLC that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. He and his team plan to use the same methodologies to revolutionize the treatments of several other common ailments and other chronic diseases.
For more information on Itonis, Inc., please visit www.itonisholdings.com.
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.